NCT06600568

Novel Therapeutic Approach for Human T-cell Malignancies

Identification of Targetable Vulnerabilities in Redox Homeostasis Pathways as a Novel Therapeutic Approach for Human T-cell Malignancies

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 120 (estimated)
• Sponsor: Istituto Oncologico Veneto IRCCS · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This multicenter translational study, with prospective and retrospective samples, aims to identify new strategies to selectively eliminate neoplastic T cells by modulating intracellular ROS levels. Interactions between drugs capable of activating the apoptotic process (e.g., Venetoclax) and drugs capable of altering ROS homeostasis (e.g., inhibitors of the enzyme glucose-6-phosphate dehydrogenase) will be examined. The most promising compounds will be selected based on results obtained in vitro on cell lines and PDX already available in the laboratory, and then will be assayed ex vivo in cells obtained from patients with resistant/refractory T-cell neoplasms.

Conditions

• T-Cell Leukemia/Lymphoma, Adult

Interventions

Type	Name	Description
OTHER	Translation analysis	Novel strategies to selectively eliminate neoplastic T cells by modulating intracellular ROS levels.

Timeline

• Start date: 2024-07-01
• Primary completion: 2026-07-01
• Completion: 2026-07-01
• First posted: 2024-09-19
• Last updated: 2025-12-08

Locations

2 sites across 1 country: Italy